Old Web
English
Sign In
Acemap
>
authorDetail
>
Frédérique Jantet-Blaudez
Frédérique Jantet-Blaudez
Sanofi Pasteur
Dengue vaccine
Placebo
Medicine
Dengue fever
Dengue virus
3
Papers
18
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
2021
Human Vaccines & Immunotherapeutics
Juliana Park
Sophia Archuleta
May-Lin Helen Oh
Lynette Pei-Chi Shek
Wang Hao
Matthew Bonaparte
Carina Frago
Alain Bouckenooghe
Frédérique Jantet-Blaudez
Sarah Begue
Sophie Gimenez-Fourage
Anke Pagnon
Show All
Source
Cite
Save
Citations (0)
Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
2020
Pediatric Infectious Disease Journal
Diana Coronel
Enid J Garcia-Rivera
Doris Maribel Rivera
José Luis Arredondo-García
Reynaldo Dietze
Ana Paula Perroud
Margarita Cortés
Matthew Bonaparte
Hao Wang
Anke Pagnon
Frédérique Jantet-Blaudez
Luis Andrey Rojas Peñalosa
Gustavo H. Dayan
Betzana Zambrano
Carlos A. DiazGranados
Fernando Noriega
Show All
Source
Cite
Save
Citations (4)
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials
2016
PLOS Neglected Tropical Diseases
Anke Harenberg
Aymeric de Montfort
Frédérique Jantet-Blaudez
Matthew Bonaparte
Florence Boudet
Melanie Saville
Nicholas Jackson
Bruno Guy
Show All
Source
Cite
Save
Citations (14)
1